clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Chlamydial Pneumonia D061387 2 associated lipids
Sacroiliitis D058566 1 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgA Deficiency D017098 2 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Empyema, Pleural D016724 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Eye Infections D015817 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Ureteral Diseases D014515 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis D014376 20 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis D013587 6 associated lipids
Synovitis D013585 15 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Diseases D013272 7 associated lipids
Sporotrichosis D013174 3 associated lipids
Splenic Diseases D013158 5 associated lipids
Skin Ulcer D012883 6 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Serositis D012700 1 associated lipids
Scrub Typhus D012612 3 associated lipids
Rosacea D012393 13 associated lipids
Rodent Diseases D012376 4 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Radiation Injuries D011832 14 associated lipids
Pyelonephritis D011704 5 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Anzueto A et al. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. 1999 Clin. Infect. Dis. pmid:10451195
Gordin FM et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. 1999 Clin. Infect. Dis. pmid:10452638
Pandita D and Carson PJ Thyroid abscess caused by Mycobacterium chelonae. 1999 Clin. Infect. Dis. pmid:10452671
Härtig G et al. [Symptomatic psychosis in bland sinus thrombosis and antibiotic therapy]. 1999 Psychiatr Prax pmid:10457975
Labenz J and Stolte M [Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?]. 1999 Z Gastroenterol pmid:10458014
Boyanova L et al. Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years. 1999 Diagn. Microbiol. Infect. Dis. pmid:10459482
Sendi PP et al. Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. 1999 J Eval Clin Pract pmid:10461580
Gooderham MJ et al. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. 1999 Jul-Aug Ann Pharmacother pmid:10466907
Gschwantler M et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. 1999 Aliment. Pharmacol. Ther. pmid:10468682
Paré P et al. Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. 1999 Aliment. Pharmacol. Ther. pmid:10468683
Sung JJ et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. 1999 Aliment. Pharmacol. Ther. pmid:10468684
Catalano F et al. Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. 1999 Helicobacter pmid:10469192
Kamada T et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. 1999 Helicobacter pmid:10469195
Bui KQ et al. Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. 1999 Antimicrob. Agents Chemother. pmid:10471584
Tanaka E et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. 1999 Am. J. Respir. Crit. Care Med. pmid:10471610
Mikamo H et al. Adequate macrolide treatment schedules for uterine cervicitis caused by Chlamydia trachomatis. 1999 Sep-Oct Chemotherapy pmid:10473928
Geiderman JM Central nervous system disturbances following clarithromycin ingestion. 1999 Clin. Infect. Dis. pmid:10476775
Gómez Cubillos C et al. [Can macrolide treatment delay the diagnosis of tuberculosis?]. 1999 An Med Interna pmid:10481348
Sato K et al. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines]. 1999 Kekkaku pmid:10481412
Gidoh M [The control leprous peripheral neuropathy and chemotherapy]. 1999 Nihon Hansenbyo Gakkai Zasshi pmid:10481449
Klapper SR and Patrinely JR Periocular atypical mycobacterial infections. 1999 Ophthalmology pmid:10485521
Matsuoka M et al. Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure. 1999 Gut pmid:10486356
Tyagi AK et al. An unreported side effect of topical clarithromycin when used successfully to treat Mycobacterium avium-intracellulare keratitis. 1999 Cornea pmid:10487437
Rodríguez Téllez M et al. Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection. 1999 Rev Esp Enferm Dig pmid:10491487
Gutiérrez-Cabano CA and Raynald AC Gastroprotective effect of intragastric clarithromycin against damage induced by ethanol in rats. 1999 Dig. Dis. Sci. pmid:10492159
Moore PA Dental therapeutic indications for the newer long-acting macrolide antibiotics. 1999 J Am Dent Assoc pmid:10492541
Osato MS et al. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. 1999 Int. J. Antimicrob. Agents pmid:10493611
Hirsh DC and Jang SS Antimicrobial susceptibility of Nocardia nova isolated from five cats with nocardiosis. 1999 J. Am. Vet. Med. Assoc. pmid:10496134
Ellenrieder V et al. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. 1999 Scand. J. Gastroenterol. pmid:10499474
Zgoulli S et al. Microencapsulation of erythromycin and clarithromycin using a spray-drying technique. 1999 Sep-Oct J Microencapsul pmid:10499837
Landesman KA et al. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. 1999 Conn Med pmid:10500341
Gómez G et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. 1999 Transplant. Proc. pmid:10500563
Unge P The OAC and OMC options. 1999 Eur J Gastroenterol Hepatol pmid:10503817
Spiller RC Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? 1999 Eur J Gastroenterol Hepatol pmid:10503819
Mégraud F Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. 1999 Eur J Gastroenterol Hepatol pmid:10503821
Bazzoli F et al. What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance? 1999 Eur J Gastroenterol Hepatol pmid:10503822
Gisbert JP et al. Re-treatment after Helicobacter pylori eradication failure. 1999 Eur J Gastroenterol Hepatol pmid:10503846
Uygun A et al. Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. 1999 Clin Ther pmid:10509849
McMullin ST et al. Impact of a Web-based clinical information system on cisapride drug interactions and patient safety. 1999 Arch. Intern. Med. pmid:10510994
Furuta T et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. 1999 Clin. Pharmacol. Ther. pmid:10511062
Galil K et al. Abscesses due to mycobacterium abscessus linked to injection of unapproved alternative medication. 1999 Sep-Oct Emerging Infect. Dis. pmid:10511524
Talley NJ et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. 1999 N. Engl. J. Med. pmid:10511608
Gilljam M et al. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. 1999 Eur. Respir. J. pmid:10515412
Rovira E et al. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. 1999 Respiration pmid:10516537
Foster SF et al. Chronic pneumonia caused by Mycobacterium thermoresistibile in a cat. 1999 J Small Anim Pract pmid:10516950
Goldberg EI et al. Henoch-Schönlein purpura induced by clarithromycin. 1999 Int. J. Dermatol. pmid:10517691
Uygun A et al. Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. 1999 Am. J. Gastroenterol. pmid:10520880
Gibson JR et al. Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. 1999 J. Clin. Microbiol. pmid:10523591
Baylor P and Williams K Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy. 1999 Clin. Infect. Dis. pmid:10525003
Yoh M et al. Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. 1999 Can. J. Microbiol. pmid:10526400